BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma

  • End date
    Dec 31, 2022
  • participants needed
  • sponsor
    Shanghai Changzheng Hospital
Updated on 23 June 2021
platelet count
progressive disease
neutrophil count
serum calcium
line of therapy
proteasome inhibitor
immunomodulatory imide drug


This is a single arm, open-label, multi-center prospective study to determine the safety and efficacy of GC012F CAR-T cells in patients diagnosed with BCMA+ refractory/relapsed multiple myeloma (r/r MM).


The main aim of the study is to determine the safety and efficacy of GC012F in r/r MM. GC012F is an autologous dual chimeric antigen receptor T-cell (CAR-T) therapy that targets B-cell maturation antigen (BCMA) and CD19. This study comprises of a Screening Phase (less than or equal to [<=] 28 days prior to apheresis) followed by Apheresis (will occur upon enrollment); Treatment Phase including a conditioning regimen followed by infusion of GC012F and post-infusion assessments from Day 1 to Day 84; and a Post-treatment Phase (Day 85 and up to end of the study). Efficacy will be explored to assessed and safety will be closely monitored during the study.

Condition Lymphoproliferative disorders, Lymphoproliferative Disorder, Multiple Myeloma, multiple myeloma (mm)
Treatment GC012F injection
Clinical Study IdentifierNCT04236011
SponsorShanghai Changzheng Hospital
Last Modified on23 June 2021


Yes No Not Sure

Inclusion Criteria

Patients must have a confirmed prior diagnosis of active multiple myeloma as defined by the updated IMWG criteria
Diagnosis of MM with relapsed or refractory disease. Definition of Refractory/relapse
Have had at least 3 prior lines of therapy or primary refractory as defined by Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Prior therapy should include PI and IMiD. Note: Patients should undergone at least have at least complete 1 cycle treatment in each line. Induction with or without hematopoietic stem cell transplant followed by maintenance therapy is considered a single line of therapy
Estimated life expectancy 3 months
Have had at least 2 prior lines of therapy when refractory to both immunomodulatory drug (IMiD) and proteasome inhibitor(PI) (Refractory was defined by IMWG consensus criteria)
Hemoglobin 8.0 g/dL
Absolute neutrophil count 0.7510E9/L
Absolute lymphocyte count 110E8/L
Platelet count 5010E9/L
Liver, kidney and cardiopulmonary functions meet the following requirements: a)Total bilirubin 2ULN(except for Gilbert Syndrome); ALT and/or AST 3 ULN; b)clearance of serum creatinine 40 mL/min, calculated by Cockcroft-Gault; c)Corrected serum calcium 12.5mg/dL or free ion calcium 6.5mg/dL(1.6mmol/L)
Sufficient venous access for leukapheresis collection, and no other contraindications to leukapheresis
Subjects and sexual partner with fertility are willing to use effective and reliable method of contraception for at least 100 days after CART cell infusion
Subjects must have signed written, informed consent

Exclusion Criteria

Accompanied by other uncontrolled malignancies.There are two exceptions to this criterion: Recepted radical therapy carcinoma without activity within 3 years before screening; and fully treated skin non-melanoma
Any situations not benefit for subjects to accept or tolerated to planned therapy or understand informed consent; or any situation in which investigators believe that participation in this study is not in the subject's best interests (e.g., harm to health), or any situation that may prevent, limit or confuse the assessment
Convulsion or stoke within past 6 months
Any instability of systemic disease within 6 months prior to screening, including but not limited to congestive heart failure (New York heart association (NYHA) classification III), unstable angina, cerebrovascular accident, or transient cerebral ischemic, myocardial infarction,LEVF< 45% (assessed by an echocardiogram or multi-door circuit scan )
Patients have central nervous system (CNS) metastases or CNS involvement (including cranial neuropathies or mass lesions and leptomeningeal disease)
Subjects with positive HBsAg or HBcAb postive and peripheral blood HBV DNA titer is higher than the lower limit of detection of the research institution; HCV antibody positive; HIV antibody positive; syphilis primary screening antibody positive
Presence or suspicion of fungi, bacteria, viruses or other infections that are uncontrollable or requiring intravenous treatment
Activity of autoimmune diseases (such as crohn's disease, rheumatoid arthritis, systemic lupus erythematosus), orhistory of autoimmune disease within the last 3 years
Clinical evidence of dementia or changes of mental state
Exist of pulmonary fibrosis
Allergy subjects or history of severe hypersensitivity
Oxygen inhalation requirment to maintain adequate oxygen saturation
Surgery (except for local anesthesia surgery) plan 2 weeks before apheresis. during or 2 weeks after CART infusion
Chemotherapy forbidden for cyclophosphamide or fludarabine
Pregnant or lactating, or planning to have a pregnancy during or within 100 days after treatment
Patients who are accounted to be not appropriate for this trail by investigator
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note